Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 03, 2026 | June 04, 2026 |
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Director | June 05, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-06-03 | Direct | 74,497 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 74,497 · Balance 74,497 F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
RECURSION PHARMACEUTICALS, INC.
Report date June 05, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 883,735 |
Ending reported balance
After 2026-06-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-05 · Conversion · Acquired 40,000 · Balance 923,735 F1: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a sale of the shares by the Reporting Person. Each share of Class B Common Stock is convertible into one share of Class A Common Stock. F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Row 2 · 2026-06-05 · Sale · Disposed 40,000 · Balance 883,735 F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 4,263,334 |
Reported balance
After 2026-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-05 · Conversion · Disposed 40,000 · Balance 4,263,334 F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a sale of the shares by the Reporting Person. Each share of Class B Common Stock is convertible into one share of Class A Common Stock. F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Indirectby LAHWRAN-3 LLC | 386,000 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 386,000 F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F4: The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Indirectby LAHWRAN-4 LLC | 388,000 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 388,000 F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F5: The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Indirectby Gibson Family Trust | 50,000 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 50,000 F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F6: The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2035-02-03 | Direct | 1,050,567 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 1,050,567 F7: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.09 · Expires 2034-02-09 | Direct | 666,898 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 666,898 F8: The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2033-02-01 | Direct | 813,600 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 813,600 F9: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 399,002 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 399,002 F10: The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 5,436 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 5,436 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2030-12-30 | Direct | 282,500 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 282,500 F11: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a sale of the shares by the Reporting Person. Each share of Class B Common Stock is convertible into one share of Class A Common Stock.
F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F4: The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
F5: The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
F6: The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
F7: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F8: The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F9: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F10: The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F11: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2025 Filed Feb 7, 2025 21:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $7.68 | $153,600.00 |
DisclosureSEC source: 0001601830-25-000014 · wk-form4_1738962869.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,273,156 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000014 · wk-form4_1738962869.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,293,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a bona-fide gift of shares by the Reporting Person F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 1,050,567 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001628280-25-004085 · wk-form4_1738792209.xml · derivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,050,567 Underlying: Class A Common Stock · 1,050,567 shares Expires 2035-02-03 F4 · derivative.exercise_date: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 5,569 | $7.25 | $40,375.25 |
DisclosureSEC source: 0001628280-25-004085 · wk-form4_1738792209.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,273,156 F3 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 16,809 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-004085 · wk-form4_1738792209.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,278,725 F2 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 525,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-004085 · wk-form4_1738792209.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,261,916 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2025 and every three months thereafter. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000010 · wk-form4_1736807155.xml · derivative · entry 6 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,976,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $7.05 | $141,000.00 |
DisclosureSEC source: 0001601830-25-000010 · wk-form4_1736807155.xml · nonDerivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 736,633 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000010 · wk-form4_1736807155.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 756,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| January 08, 2025 Filed Jan 13, 2025 22:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000010 · wk-form4_1736807155.xml · derivative · entry 5 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,996,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| January 08, 2025 Filed Jan 13, 2025 22:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $7.31 | $146,200.00 |
DisclosureSEC source: 0001601830-25-000010 · wk-form4_1736807155.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 736,633 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| January 08, 2025 Filed Jan 13, 2025 22:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000010 · wk-form4_1736807155.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 756,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 22:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000234 · wk-form4_1733525191.xml · derivative · entry 6 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,016,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 22:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $7.12 | $142,400.00 |
DisclosureSEC source: 0001601830-24-000234 · wk-form4_1733525191.xml · nonDerivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 736,633 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 22:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000234 · wk-form4_1733525191.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 756,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 22:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000234 · wk-form4_1733525191.xml · derivative · entry 5 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,036,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 22:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $7.16 | $143,200.00 |
DisclosureSEC source: 0001601830-24-000234 · wk-form4_1733525191.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 736,633 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 22:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000234 · wk-form4_1733525191.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 756,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 23:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 26,023 | $6.18 | $160,692.03 |
DisclosureSEC source: 0001601830-24-000212 · wk-form4_1732058760.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 736,633 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| November 14, 2024 Filed Nov 15, 2024 23:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000207 · wk-form4_1731714767.xml · derivative · entry 6 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,056,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| November 14, 2024 Filed Nov 15, 2024 23:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $7.35 | $147,000.00 |
DisclosureSEC source: 0001601830-24-000207 · wk-form4_1731714767.xml · nonDerivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 762,656 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| November 14, 2024 Filed Nov 15, 2024 23:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000207 · wk-form4_1731714767.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 782,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 23:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000207 · wk-form4_1731714767.xml · derivative · entry 5 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,076,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 23:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $7.74 | $154,800.00 |
DisclosureSEC source: 0001601830-24-000207 · wk-form4_1731714767.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 762,656 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 23:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000207 · wk-form4_1731714767.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 782,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 22:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000172 · wk-form4_1728081003.xml · derivative · entry 6 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,096,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 22:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $6.08 | $121,600.00 |
DisclosureSEC source: 0001601830-24-000172 · wk-form4_1728081003.xml · nonDerivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 762,656 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 22:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000172 · wk-form4_1728081003.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 782,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 22:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000172 · wk-form4_1728081003.xml · derivative · entry 5 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,116,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 22:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $6.16 | $123,200.00 |
DisclosureSEC source: 0001601830-24-000172 · wk-form4_1728081003.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 762,656 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 22:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000172 · wk-form4_1728081003.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 782,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| September 05, 2024 Filed Sep 6, 2024 20:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000155 · wk-form4_1725656242.xml · derivative · entry 6 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,136,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F2 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| September 05, 2024 Filed Sep 6, 2024 20:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $6.14 | $122,800.00 |
DisclosureSEC source: 0001601830-24-000155 · wk-form4_1725656242.xml · nonDerivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 762,656 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| September 05, 2024 Filed Sep 6, 2024 20:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000155 · wk-form4_1725656242.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 782,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F2 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. Read SEC document |
| September 04, 2024 Filed Sep 6, 2024 20:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000155 · wk-form4_1725656242.xml · derivative · entry 5 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,156,700 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F2 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| September 04, 2024 Filed Sep 6, 2024 20:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $6.04 | $120,800.00 |
DisclosureSEC source: 0001601830-24-000155 · wk-form4_1725656242.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 762,656 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| September 04, 2024 Filed Sep 6, 2024 20:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-24-000155 · wk-form4_1725656242.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 782,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. F2 · kind: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person. Read SEC document |
| August 30, 2024 Filed Aug 30, 2024 20:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001601830-24-000145 · wk-form4_1725049600.xml · derivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,500 Underlying: Class A Common Stock · 5,000 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| August 30, 2024 Filed Aug 30, 2024 20:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 5,000 | $2.48 | $12,400.00 |
DisclosureSEC source: 0001601830-24-000145 · wk-form4_1725049600.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 762,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2024 Filed Aug 29, 2024 20:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001601830-24-000144 · wk-form4_1724962960.xml · derivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,500 Underlying: Class A Common Stock · 5,000 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| August 29, 2024 Filed Aug 29, 2024 20:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 5,000 | $2.48 | $12,400.00 |
DisclosureSEC source: 0001601830-24-000144 · wk-form4_1724962960.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 757,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2024 Filed Aug 28, 2024 20:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001628280-24-038664 · wk-form4_1724875958.xml · derivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,500 Underlying: Class A Common Stock · 5,000 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| August 28, 2024 Filed Aug 28, 2024 20:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 5,000 | $2.48 | $12,400.00 |
DisclosureSEC source: 0001628280-24-038664 · wk-form4_1724875958.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 752,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2024 Filed Aug 27, 2024 20:10 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001628280-24-038532 · wk-form4_1724789427.xml · derivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,500 Underlying: Class A Common Stock · 5,000 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| August 27, 2024 Filed Aug 27, 2024 20:10 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 5,000 | $2.48 | $12,400.00 |
DisclosureSEC source: 0001628280-24-038532 · wk-form4_1724789427.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 747,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 20:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001628280-24-038438 · wk-form4_1724704942.xml · derivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,500 Underlying: Class A Common Stock · 5,000 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 20:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 5,000 | $2.48 | $12,400.00 |
DisclosureSEC source: 0001628280-24-038438 · wk-form4_1724704942.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 742,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2024 Filed Aug 23, 2024 21:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001601830-24-000130 · wk-form4_1724448315.xml · derivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,500 Underlying: Class A Common Stock · 5,000 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| August 23, 2024 Filed Aug 23, 2024 21:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 5,000 | $2.48 | $12,400.00 |
DisclosureSEC source: 0001601830-24-000130 · wk-form4_1724448315.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 737,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 23:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 26,082 | $6.69 | $174,488.58 |
DisclosureSEC source: 0001601830-24-000126 · wk-form4_1724108966.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732,656 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.